Sanofi/ US80105N1054 /
2024-05-31 10:00:00 PM | Chg. +1.2000 | Volume | Bid10:59:20 PM | Ask10:59:20 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
49.0300USD | +2.51% | 2.1 mill. Turnover: 59.6 mill. |
47.5000Bid Size: 100 | 50.0000Ask Size: 500 | 122.11 bill.USD | - | - |
GlobeNewswire
7:05 AM
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
7:05 AM
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
7:00 AM
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
7:00 AM
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
05-27
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
05-21
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
05-08
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update